Combination Treatment for CLL

The results from a phase II multicentre study in which older (≥65 years), previously untreated patients with chronic lymphocytic leukaemia received a combination of pentostatin, cyclophosphamide and ofatumumab were presented

at the 2013 American Society of Hematology 2013 annual meeting. This combination was used because of the reported efficacy of chemo immunotherapy (CIT), the combined used of chemotherapy with monoclonal antibodies, in CLL as well as the activity and toxicity of combinations in which pentostatin is used. Patients (n = 49) were included in the analysis. The overall response rate, the primary end point, was 93.7%. The efficacy of the ofatumumab-based CIT compared favourably with rituximab-based CIT regimens that have been used in the past.

For more information, click here.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Do you understand how cancer drugs are approved in your country?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.